

APAC DA-EWG Session
**"How to establish drug discovery
ecosystem in Asia"**

Atsushi Hasuoka, Ph.D., MBA

APAC DA-EWG

JPMA R&D Subcommittee

Objectives of DA session

- 1. Share progress of Pillar 5, drug discovery using natural products**
 - ✓ **Guideline**
 - ✓ **Pilot project, etc.**
- 2. Reach consensus on the potential & importance of "drug discovery ecosystem in Asia" as a foundation for effective cross-border open innovation in Asia**
- 2. Discuss key points in establishing "drug discovery ecosystem in Asia"**


Mission and Strategy of DA

Mission

Promote cross-border open innovation to develop innovative medicines for patients in Asia

Strategy

Focus on critical drug R&D processes and promote them in collaboration with Asian countries



JPMA delegation to Asian countries

- May, 2017 China Pharmaceutical Industry Research and Development Association
Yabao and 10 bioventures in Suzhou bioBAY
- June, 2017 Industrial Technology Research Institute
Taiwan Bio Bank in Academia Sinica
Bio Business Asia conference
Immunology Research Center, National Health Research Institute
Development Center for Biotechnology
- Sep., 2017 Mahidol University (Faculty of Tropical Medicine, Center of Excellence for Biomedical and Public Health Informatics, Excellent Center for Drug Discovery)
Chulalongkorn University (Faculty of Pharmaceutical Science, Stem Cell and Cell Therapy Research Unit)
BIOTEC / National Science and Technology Development Agency
Medical Genomics Center

JPMA delegation to Asian countries

- Oct., 2017 China BioMed Innovation and Investment Conference
12 bioventures in Suzhou bioBAY
Shanghai Hengrui Pharmaceutical
Shanghai Institute Materia Medica/Chinese Academy of Science
- Jan., 2018 Singapore branch office of Japan Agency for Medical Research
and Development
Cancer Research Malaysia
University of Malaya, Faculty of Medicine
Malaysian Institute of Pharmaceuticals and Nutraceuticals
BIOTEC / National Science and Technology Development Agency,
Thailand
Thailand Center of Excellence for Life Sciences

5 countries, 30 research organizations



Learning from JPMA site visits

Many chances of successful
cross-border open innovation
in Asia


How to promote cross-border open
innovation in Asia?

Drug Discovery Ecosystem
in Asia

DA Session Theme


"Drug Discovery Ecosystem"

- Consists of academia, industry, government and patients/doctors
- Foundation of successful drug discovery and open innovation
- Critical to generate new drugs fulfilling patients' needs



"Drug Discovery Ecosystem in Asia"

- Increases chances to find best collaboration partners
- Critical to realize sustainable open innovation in Asia
- Critical to generate medicines for **Asian people (APAC Mission)**



Features of Asia increasing the value of "Drug Discovery Ecosystem "

People

- ✓ Asia accounts for 60% of the world population




Economy

- ✓ Many of the Asian countries on the way of the economic growth



Geographical proximity

- ✓ Geographical proximity between Asian countries will benefit effective communication & collaboration



Session program

Presentation

- Dr. Nares TCELS (Thailand)
- Mr. Kono AMED (Japan)
- Dr. Wang Yabao (China)
- Dr. Nishimura Mie Univ. (Japan)
- Dr. Wu DCB (Taiwan)

Panel Discussion

Discuss how to establish "Drug Discovery Ecosystem in Asia"

- ✓ Key points & challenges
- ✓ Contribution of Pillar 5, etc.

**"Drug Discovery Ecosystem in Asia"
has larger potential than the ecosystem
of each Asian country**

